Coastline Trust Co increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 22.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,125 shares of the biopharmaceutical company’s stock after buying an additional 1,120 shares during the quarter. Coastline Trust Co’s holdings in Gilead Sciences were worth $434,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. lifted its position in Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its position in Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. American Beacon Advisors Inc. purchased a new position in Gilead Sciences during the first quarter worth about $143,000. Sterling Investment Advisors Ltd. purchased a new position in Gilead Sciences during the second quarter worth about $184,000. Finally, Washington Trust Bank lifted its position in Gilead Sciences by 24.8% during the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock worth $196,000 after buying an additional 550 shares during the period. Hedge funds and other institutional investors own 74.62% of the company’s stock.
Several brokerages have commented on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Vetr lowered Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and set a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and an average target price of $84.87.
In related news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the sale, the executive vice president now directly owns 77,363 shares in the company, valued at approximately $5,788,299.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 666,819 shares of company stock worth $52,303,086. 1.30% of the stock is owned by insiders.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.44 on Friday. The stock has a market capitalization of $94,560.00, a P/E ratio of 7.43, a P/E/G ratio of -1.19 and a beta of 1.13. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. The business had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue was down 13.2% on a year-over-year basis. During the same quarter last year, the business posted $2.75 EPS. analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.87%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.